15.9800.68% ( -0.110 )
Closed: Nov 16, 16:00:00 (EDT)Profile
About

Bambusa Therapeutics
BBTX.US
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Profile
- Company Name
- Bambusa Therapeutics, Inc.
- Market
- NasdaqGS
- Founded
- Industry
- --
- Fiscal Year End
- --
- Website
- www.bambusatx.com
Related Securities
Industry
Industry RankingsValueRank
Management
NamePosition
